[go: up one dir, main page]

MX346763B - Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. - Google Patents

Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.

Info

Publication number
MX346763B
MX346763B MX2012003694A MX2012003694A MX346763B MX 346763 B MX346763 B MX 346763B MX 2012003694 A MX2012003694 A MX 2012003694A MX 2012003694 A MX2012003694 A MX 2012003694A MX 346763 B MX346763 B MX 346763B
Authority
MX
Mexico
Prior art keywords
acne
ddo
semi
topical composition
eliminating
Prior art date
Application number
MX2012003694A
Other languages
English (en)
Other versions
MX2012003694A (es
Inventor
Vázquez Cervantes Laura
Agustín Rogelio Magaña Castro José
Peña Santoyo Pedro
Socorro Armendariz Borunda Juan
Original Assignee
Cell Therapy And Tech S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy And Tech S A De C V filed Critical Cell Therapy And Tech S A De C V
Priority to MX2012003694A priority Critical patent/MX346763B/es
Priority to PCT/MX2013/000027 priority patent/WO2013147577A1/es
Priority to AU2013240709A priority patent/AU2013240709A1/en
Priority to IN8067DEN2014 priority patent/IN2014DN08067A/en
Priority to MA37377A priority patent/MA20150062A1/fr
Priority to JP2015503144A priority patent/JP2015513359A/ja
Priority to EP13716457.0A priority patent/EP2832354A1/en
Priority to US14/388,447 priority patent/US20150148382A1/en
Priority to EA201401031A priority patent/EA201401031A1/ru
Priority to SG11201406035VA priority patent/SG11201406035VA/en
Priority to CN201380023489.8A priority patent/CN104334171A/zh
Priority to KR1020147030122A priority patent/KR20140146144A/ko
Priority to CA2868729A priority patent/CA2868729C/en
Priority to UY0001034700A priority patent/UY34700A/es
Priority to ARP130100926A priority patent/AR090457A1/es
Publication of MX2012003694A publication Critical patent/MX2012003694A/es
Priority to TNP2014000396A priority patent/TN2014000396A1/fr
Priority to IL234816A priority patent/IL234816A0/en
Priority to CO14211037A priority patent/CO7071140A2/es
Priority to PH12014502154A priority patent/PH12014502154A1/en
Priority to CU2014000114A priority patent/CU20140114A7/es
Priority to CL2014002591A priority patent/CL2014002591A1/es
Priority to DO2014000218A priority patent/DOP2014000218A/es
Priority to US15/098,970 priority patent/US9949959B2/en
Publication of MX346763B publication Critical patent/MX346763B/es
Priority to US15/920,822 priority patent/US20180214434A1/en
Priority to US16/534,980 priority patent/US11013727B2/en
Priority to US17/328,685 priority patent/US11766426B2/en
Priority to US18/449,747 priority patent/US20240216350A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe una composición tópica semisólida conteniendo Pirfenidona y un antimicrobiano/antiséptico como Dialil Óxido de Disulfuro Modificado (ODD-M) y su proceso de fabricación, que ofrece ventajas sobre otras formas farmacéuticas de administración cutánea conocidas en el estado de la técnica, que es útil como agente anti-fibrótico, anti-inflamatorio y antiséptico en la prevención, tratamiento y reversión del acné y las lesiones post-acnéicas. Dicha composición también es útil para disminuir el tono rojizo de la piel, para detener la formación de nuevos brotes de acné, para revertir los brotes ya existentes y para regenerar la piel dañada a consecuencia del acné.
MX2012003694A 2012-03-28 2012-03-28 Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. MX346763B (es)

Priority Applications (27)

Application Number Priority Date Filing Date Title
MX2012003694A MX346763B (es) 2012-03-28 2012-03-28 Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
PCT/MX2013/000027 WO2013147577A1 (es) 2012-03-28 2013-02-27 Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné
AU2013240709A AU2013240709A1 (en) 2012-03-28 2013-02-27 Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne
IN8067DEN2014 IN2014DN08067A (es) 2012-03-28 2013-02-27
MA37377A MA20150062A1 (fr) 2012-03-28 2013-02-27 Composition topique semi-solide contenant de la pirfénidone et de l'oxyde de disulfure dialyle modifié (odd-m) pour éliminer ou prévenir l'acné
JP2015503144A JP2015513359A (ja) 2012-03-28 2013-02-27 座瘡の排除又は予防用のピルフェニドンと改変ジアリルジスルフィド酸化物（ｍ−ｄｄｏ）とを含む半固形局所組成物
EP13716457.0A EP2832354A1 (en) 2012-03-28 2013-02-27 Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne
US14/388,447 US20150148382A1 (en) 2012-03-28 2013-02-27 Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne
EA201401031A EA201401031A1 (ru) 2012-03-28 2013-02-27 Полутвёрдая композиция для местного применения, которая содержит пирфенидон и модифицированный диаллилдисульфид оксид (m-ddo) для удаления или предупреждения угрей
SG11201406035VA SG11201406035VA (en) 2012-03-28 2013-02-27 Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne
CN201380023489.8A CN104334171A (zh) 2012-03-28 2013-02-27 用于消除或预防痤疮的包含吡非尼酮和改性二烯丙基二硫化物氧化物(m-ddo)的半固体局部组合物
KR1020147030122A KR20140146144A (ko) 2012-03-28 2013-02-27 여드름을 제거 또는 예방하기 위한 피르페니돈과 변성 다이알릴 다이설파이드 옥사이드(ｍ-ｄｄｏ)를 함유하는 반고체 국소 조성물
CA2868729A CA2868729C (en) 2012-03-28 2013-02-27 Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (m-ddo) for eliminating or preventing acne
UY0001034700A UY34700A (es) 2012-03-28 2013-03-20 Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné
ARP130100926A AR090457A1 (es) 2012-03-28 2013-03-21 Composicion topica semisolida conteniendo pirfenidona y dialil oxido de disulfuro modificado (odd-m) para eliminar o prevenir el acne
TNP2014000396A TN2014000396A1 (en) 2012-03-28 2014-09-22 Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne
IL234816A IL234816A0 (en) 2012-03-28 2014-09-23 A semi-solid topical preparation containing pirfenidone and modified diallyl disulfide oxide for the treatment or prevention of acne
CO14211037A CO7071140A2 (es) 2012-03-28 2014-09-24 Composición topica semisolida conteniendo pirfenidona y dialil oxido de disulfuro modificado (odd-m) para eliminar o prevenir el acne
DO2014000218A DOP2014000218A (es) 2012-03-28 2014-09-26 Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné
CU2014000114A CU20140114A7 (es) 2012-03-28 2014-09-26 Compisición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné
PH12014502154A PH12014502154A1 (en) 2012-03-28 2014-09-26 Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne
CL2014002591A CL2014002591A1 (es) 2012-03-28 2014-09-26 Composicion topica semisolida que comprende pirfenidona, dialil oxido de disulfuro modificado (odd-m), un agente gelificante y otros excipientes o aditivos; proceso para fabricarla; metodo de tratamiento; y su uso para eliminar, reducir o prevenir el acne.
US15/098,970 US9949959B2 (en) 2012-03-28 2016-04-14 Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne
US15/920,822 US20180214434A1 (en) 2012-03-28 2018-03-14 Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (m-ddo) for eliminating or preventing acne
US16/534,980 US11013727B2 (en) 2012-03-28 2019-08-07 Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne
US17/328,685 US11766426B2 (en) 2012-03-28 2021-05-24 Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne
US18/449,747 US20240216350A1 (en) 2012-03-28 2023-08-15 Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (m-ddo) for eliminating or preventing acne

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012003694A MX346763B (es) 2012-03-28 2012-03-28 Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.

Publications (2)

Publication Number Publication Date
MX2012003694A MX2012003694A (es) 2013-09-30
MX346763B true MX346763B (es) 2017-03-31

Family

ID=48096131

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003694A MX346763B (es) 2012-03-28 2012-03-28 Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.

Country Status (22)

Country Link
US (6) US20150148382A1 (es)
EP (1) EP2832354A1 (es)
JP (1) JP2015513359A (es)
KR (1) KR20140146144A (es)
CN (1) CN104334171A (es)
AR (1) AR090457A1 (es)
AU (1) AU2013240709A1 (es)
CA (1) CA2868729C (es)
CL (1) CL2014002591A1 (es)
CO (1) CO7071140A2 (es)
CU (1) CU20140114A7 (es)
DO (1) DOP2014000218A (es)
EA (1) EA201401031A1 (es)
IL (1) IL234816A0 (es)
IN (1) IN2014DN08067A (es)
MA (1) MA20150062A1 (es)
MX (1) MX346763B (es)
PH (1) PH12014502154A1 (es)
SG (1) SG11201406035VA (es)
TN (1) TN2014000396A1 (es)
UY (1) UY34700A (es)
WO (1) WO2013147577A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
CN106491517B (zh) * 2016-11-23 2019-12-06 佛山科学技术学院 吡非尼酮pva水凝胶的制备方法及吡非尼酮pva水凝胶
US20180360751A1 (en) * 2017-06-19 2018-12-20 Advanced Fibrosis Research LLC Transdermal cream for treating Dupuytren's Contracture
MX366086B (es) * 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
MX368750B (es) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
GB1458048A (en) 1972-12-18 1976-12-08 Affiliated Med Res Pharmaceutical composition
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
JPS51128433A (en) 1975-04-30 1976-11-09 Ajinomoto Co Inc A herbicide
SE430609B (sv) 1976-12-21 1983-11-28 Sca Development Ab Sett att ur cellulosaderivat framstella absorberande material
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
CA2161648A1 (en) 1993-05-07 1994-11-24 Solomon B. Margolin Compositions and methods for reparation and prevention of fibrotic lesions
PL186795B1 (pl) 1995-12-21 2004-02-27 Pfizer Preparat farmaceutyczny zawierający danofloksacynę
US5958420A (en) 1997-03-13 1999-09-28 Nortrade Medical, Inc. Treatment of burns, cuts, and abrasions of the skin
US6365131B1 (en) 1997-10-31 2002-04-02 J. B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic
ATE266405T1 (de) 1998-03-17 2004-05-15 Solomon B Margolin Topische antiseptische zusammenstellungen und methoden
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
EP1113798B1 (en) 1998-09-18 2003-01-02 Mepha AG Topical formulation of alkyl-, phenyl-pyridone
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
IN191090B (es) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
US7867516B2 (en) 2001-01-29 2011-01-11 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
AU2002348534A1 (en) 2001-10-09 2003-04-22 The Children's Hospital Of Philadelphia Materials and methods for preventing or reducing scar formation
CH696420A5 (de) 2002-09-13 2007-06-15 Mepha Ag Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung.
WO2004073713A1 (ja) 2003-02-21 2004-09-02 Shionogi & Co., Ltd. ピルフェニドンのゲル剤
AU2003225670A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003299962A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
US20060198823A1 (en) 2003-04-04 2006-09-07 Blatt Lawrence M Compositions and methods for treating viral infections
EP1638625A4 (en) * 2003-05-23 2009-08-19 David M Ott ORGANOSOUFRES PROMEDICAMENTS FOR PREVENTING AND TREATING INFECTIOUS DISEASES AND A PATHOLOGICAL REACTION OF THE IMMUNE SYSTEM
WO2005000227A2 (en) 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
OA13315A (en) 2003-10-14 2007-04-13 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US20070258946A1 (en) 2003-12-23 2007-11-08 Blatt Lawrence M Combination Therapy for Treating Hepatitis C Virus Infection
CN100542532C (zh) 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
US20060051339A1 (en) 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US20060115503A1 (en) 2004-11-30 2006-06-01 Goyal Muna C Composition, system and method for treatment of skin
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
NZ565059A (en) 2005-07-25 2011-08-26 Intermune Inc Novel macrocyclic inhibitors of hepatitus C virus replication
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US20110034495A1 (en) 2005-11-23 2011-02-10 Intermune, Inc. Method of Modulating Stress-Activated Protein Kinase System
EP1973525B1 (en) 2005-12-05 2014-04-30 RBA Pharma Inc. Emulsion-containing medical articles
CN101088557A (zh) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
JP2010518125A (ja) 2007-02-12 2010-05-27 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規な阻害剤
US20100069319A1 (en) 2007-03-02 2010-03-18 Talia Miron Mercaptopurine derivatives and uses thereof
US20080287508A1 (en) 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
ES2400026T3 (es) 2007-06-20 2013-04-05 Auspex Pharmaceuticals, Inc. N-arilpiridinonas sustituidas como inhibidores fibróticos
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
US20090137354A1 (en) 2007-11-27 2009-05-28 Shimano Inc. Bicycle rear derailleur
CN102105492A (zh) 2007-12-11 2011-06-22 科达治疗公司 受损伤口愈合的组合物和治疗
US20100256031A1 (en) 2008-10-10 2010-10-07 Jeffrey Wu Shine control cleanser
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CN101972236A (zh) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
CN101972225A (zh) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的凝胶组合物
AU2012212269B2 (en) 2011-01-31 2016-05-19 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP2675449B1 (en) 2011-02-15 2019-04-24 Aclaris Therapeutics, Inc. Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
CN102670600A (zh) 2011-03-12 2012-09-19 赵海静 一种抑制瘢痕和促进创口愈合的医药产品,其制备方法和应用
CN102670632A (zh) 2011-03-12 2012-09-19 赵海静 吡非尼酮在抑制皮肤瘢痕形成的医药用途
US9241921B2 (en) 2011-05-02 2016-01-26 Pankaj Modi Photosensitizer composition for treating skin disorders
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
WO2013181691A1 (en) 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
BR112014030623A2 (pt) 2012-06-12 2017-06-27 Hoffmann La Roche composição, combinação e respectivos usos
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
EP2968572A1 (en) 2013-03-15 2016-01-20 Medicis Pharmaceutical Corporation Topical compositions of flunisolide and methods of treatment
MX352342B (es) 2013-07-12 2017-11-22 Moleculas Naturales S A De C V Star Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos.
CN103550242B (zh) 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
GB201508419D0 (en) 2015-05-15 2015-07-01 Cambridge Entpr Ltd Detection of T cell exhaustion or lack of T cell costimulation and uses thereof
JPWO2017104725A1 (ja) 2015-12-16 2018-10-04 第一三共株式会社 創傷治療剤
JOP20170113B1 (ar) 2016-05-09 2023-03-28 Bayer Pharma AG مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
MX364040B (es) 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.

Also Published As

Publication number Publication date
CL2014002591A1 (es) 2015-01-16
IL234816A0 (en) 2014-12-31
US20200061040A1 (en) 2020-02-27
US20180214434A1 (en) 2018-08-02
PH12014502154A1 (en) 2014-12-10
AU2013240709A1 (en) 2014-11-06
US20160228424A1 (en) 2016-08-11
EA201401031A1 (ru) 2015-05-29
US20240216350A1 (en) 2024-07-04
SG11201406035VA (en) 2014-11-27
US11766426B2 (en) 2023-09-26
US9949959B2 (en) 2018-04-24
US20210346360A1 (en) 2021-11-11
DOP2014000218A (es) 2014-12-15
CA2868729A1 (en) 2013-10-03
IN2014DN08067A (es) 2015-05-01
CU20140114A7 (es) 2015-01-29
US20150148382A1 (en) 2015-05-28
MA20150062A1 (fr) 2015-02-27
UY34700A (es) 2013-10-31
CN104334171A (zh) 2015-02-04
KR20140146144A (ko) 2014-12-24
TN2014000396A1 (en) 2015-12-21
JP2015513359A (ja) 2015-05-11
WO2013147577A1 (es) 2013-10-03
CA2868729C (en) 2020-10-20
MX2012003694A (es) 2013-09-30
AR090457A1 (es) 2014-11-12
CO7071140A2 (es) 2014-09-30
US11013727B2 (en) 2021-05-25
EP2832354A1 (en) 2015-02-04

Similar Documents

Publication Publication Date Title
PH12014502154A1 (en) Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne
MX2018000421A (es) Composiciones de retinoides topicos.
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
WO2015095811A8 (en) Combination therapy with neoantigen vaccine
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2015DN02573A (es)
AU2014359194A1 (en) Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use thereof in dermatology
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
MX366773B (es) Composicion topica para lavado para su uso en pacientes con acne.
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2012050831A3 (en) Combination treatment for dermatological conditions
MX363993B (es) Composiciones farmaceuticas con actividad hidratante y lubricante.
MX2016003951A (es) Composicion para rocio topica de halobetasol.
WO2014030992A3 (es) Composición antiséptica, seborreguladora y exfoliante para tratar o prevenir el acné
TN2015000282A1 (fr) Composition dermatologique antimicrobienne topique
FR2978665B1 (fr) Composition antiseptique
MX357704B (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
WO2013092457A3 (de) Wirkstoffkombinationen aus einer oder mehreren carbonsäuren, insbesondere hydroxycarbonsäuren, und einer oder mehreren physiologisch unbedenklichen hydroxamsäure sowie kosmetische oder dermatologische zubereitungen, solche wirkstoffkombinationen enthaltend
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
TN2015000142A1 (en) Use of pidotimod to treat psoriasis
MX2016003950A (es) Composicion para rocio topica de halobetasol sin propelente.
PH12016500471A1 (en) Method to treat onychomycosis by hydroxypropyl chitosan
HK1192152A1 (zh) 新型抗红班活性剂和含相同的组合物
MX343284B (es) Extracto acuoso de ageratina pichinchensis y uso para el tratamiento de cicatrizacion de heridas.
LV14644A (lv) Krēms psoriāzes izraisītu patoloģisku ādas izmaiņu ārstēšanai

Legal Events

Date Code Title Description
FG Grant or registration